Edition:
United States

Morphosys AG (MORG.DE)

MORG.DE on Xetra

56.73EUR
18 Aug 2017
Change (% chg)

€-0.47 (-0.82%)
Prev Close
€57.20
Open
€56.83
Day's High
€56.93
Day's Low
€56.11
Volume
130,349
Avg. Vol
171,760
52-wk High
€68.73
52-wk Low
€35.61

MORG.DE

Chart for MORG.DE

About

MorphoSys AG develops and commercializes antibodies for therapeutic applications. The Company develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The Company's operating segments include Proprietary Development and Partnered Discovery. In the Proprietar... (more)

Overall

Beta: 0.75
Market Cap(Mil.): €1,663.93
Shares Outstanding(Mil.): 29.33
Dividend: --
Yield (%): --

Financials

  MORG.DE Industry Sector
P/E (TTM): -- 78.89 32.56
EPS (TTM): -2.61 -- --
ROI: -19.28 2.83 14.89
ROE: -19.78 5.09 16.13

BRIEF-Morphosys affirms guidance after Q2 results

* dgap-news: morphosys reports significant progress in its therapeutic programs in second quarter of 2017

Aug 03 2017

Morphosys sees revenue boost from Janssen psoriasis drug

DUESSELDORF/FRANKFURT German biotech group Morphosys expects to receive royalties from psoriasis drug guselkumab for five months this year, its Chief Executive Simon Moroney said, after its licensee received U.S. regulatory approval.

Jul 14 2017

REFILE-UPDATE 3-Morphosys sees revenue boost from Janssen psoriasis drug

DUESSELDORF/FRANKFURT, July 14 German biotech group Morphosys expects to receive royalties from psoriasis drug guselkumab for five months this year, its Chief Executive Simon Moroney said, after its licensee received U.S. regulatory approval.

Jul 14 2017

Morphosys sees revenue boost from Janssen psoriasis drug

DUESSELDORF/FRANKFURT German biotech group Morphosys expects to receive royalties from psoriasis drug guselkumab for five months this year, its Chief Executive Simon Moroney said, after its licensee received U.S. regulatory approval.

Jul 14 2017

BRIEF-Morphosys CEO sees 5 months of guselkumab royalties this year

* Says he expects royalties for 5 months this year after U.S. Approval of guselkumab

Jul 14 2017

Morphosys jumps pre-market as FDA approves antibody drug

FRANKFURT, July 14 Shares in Morphosys jumped 11 percent in pre-market trade on Friday after a licensee won U.S. approval for psoriasis drug guselkumab, bringing the German biotech group a step closer to launching its first antibody drug onto the market.

Jul 14 2017

BRIEF-Morphosys presents data from phase 2 clinical trial with MOR208 in patients with DLBCL

* MORPHOSYS PRESENTS FIRST SAFETY AND EFFICACY DATA OF MOR208 IN COMBINATION WITH LENALIDOMIDE FROM A PHASE 2 STUDY IN DLBCL

Jun 05 2017

BRIEF-Morphosys: Janssen updates on development of guselkumab

* ANNOUNCES THAT ITS LICENSEE JANSSEN REPORTED UPDATES ON DEVELOPMENT OF GUSELKUMAB

May 24 2017

BRIEF-Morphosys confirms 2017 outlook after Q1 loss widens

* Group revenues amounted to eur 11.8 million, in line with level of q1 of 2016

May 03 2017

BRIEF-Morphosys chief scientific officer takes temporary leave

* Says CSO Marlies Sproll takes temporary leave, Markus Enzelberger to serve as interim CSO

Mar 23 2017

Earnings vs. Estimates